Skip to main content

Advertisement

Springer Nature Link
Log in

Hypertriglyceridemia: phenomics and genomics

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Hypertriglyceridemia is a common complex metabolic trait that is associated with increased atherosclerosis risk, presence of the metabolic syndrome and, with extreme elevation, increased risk of pancreatitis. Hierarchical cluster analysis using clinical and biochemical features of the Frederickson hyperlipoproteinemia types can generate hypotheses for molecular genetic studies. High throughput resequencing of individuals at the extremes of plasma triglyceride concentration has shown that both rare genetic variants with large effects and common genetic variants with moderate effects explain a relatively large proportion of variation. Very recent progress using high-density sets of genome-wide markers have identified additional genetic determinants of plasma triglyceride concentrations, albeit within largely normolipidemic subjects and with small effect sizes. Phenomic evaluation of patients with hypertriglyceridemia might help to clarify genotype–phenotype correlations and responses to interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yuan G, Al-Shali KZ, Hegele RA (2007) Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 176:1113–1120. doi:10.1503/cmaj.060963

    PubMed  Google Scholar 

  2. Goldberg IJ (1996) Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 37:693–707

    PubMed  CAS  Google Scholar 

  3. Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40:1–16

    PubMed  CAS  Google Scholar 

  4. Breckenridge WC, Little JA, Steiner G et al (1978) Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 298:1265–1273

    PubMed  CAS  Google Scholar 

  5. Pennacchio LA, Olivier M, Hubacek JA et al (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173. doi:10.1126/science.1064852

    Article  PubMed  CAS  Google Scholar 

  6. Beigneux AP, Davies BS, Gin P et al (2007) Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 5:279–291. doi:10.1016/j.cmet.2007.02.002

    Article  PubMed  CAS  Google Scholar 

  7. Herz J (1993) The LDL-receptor-related protein—portrait of a multifunctional receptor. Curr Opin Lipidol 4:107–113. doi:10.1097/00041433-199304000-00006

    Article  CAS  Google Scholar 

  8. Criqui MH, Heiss G, Cohn R et al (1993) Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328:1220–1225. doi:10.1056/NEJM199304293281702

    Article  PubMed  CAS  Google Scholar 

  9. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219. doi:10.1097/00043798-199604000-00014

    Article  PubMed  CAS  Google Scholar 

  10. Bansal S, Buring JE, Rifai N et al (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316. doi:10.1001/jama.298.3.309

    Article  PubMed  CAS  Google Scholar 

  11. Nordestgaard BG, Benn M, Schnohr P et al (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308. doi:10.1001/jama.298.3.299

    Article  PubMed  CAS  Google Scholar 

  12. Benlian P, De Gennes JL, Foubert L et al (1996) Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335:848–854. doi:10.1056/NEJM199609193351203

    Article  PubMed  CAS  Google Scholar 

  13. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60:473–485

    PubMed  CAS  Google Scholar 

  14. Santamarina-Fojo S (1998) The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 27:551–567. doi:10.1016/S0889-8529(05)70025-6 viii

    Article  PubMed  CAS  Google Scholar 

  15. Hegele RA (2007) Phenomics, lamin A/C, and metabolic disease. J Clin Endocrinol Metab 92:4566–4568. doi:10.1210/jc.2007-2078

    Article  PubMed  CAS  Google Scholar 

  16. Hegele RA, Oshima J (2007) Phenomics and lamins: from disease to therapy. Exp Cell Res 313:2134–2143. doi:10.1016/j.yexcr.2007.03.023

    Article  PubMed  CAS  Google Scholar 

  17. Fredrickson DS (1993) Phenotyping. On reaching base camp (1950–1975). Circulation 87:III1–III15

    PubMed  CAS  Google Scholar 

  18. Hegele RA (2001) Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 69:1161–1177. doi:10.1086/324647

    Article  PubMed  CAS  Google Scholar 

  19. Lee JC, Lusis AJ, Pajukanta P (2006) Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Curr Opin Lipidol 17:101–109. doi:10.1097/01.mol.0000217890.54875.13

    Article  PubMed  CAS  Google Scholar 

  20. Walden CC, Hegele RA (1994) Apolipoprotein E in hyperlipidemia. Ann Intern Med 120:1026–1036

    PubMed  CAS  Google Scholar 

  21. Tall AR (2006) Protease variants, LDL, and coronary heart disease. N Engl J Med 354:1310–1312. doi:10.1056/NEJMe068026

    Article  PubMed  CAS  Google Scholar 

  22. Pollex RL, Hegele RA (2007) Genetic determinants of plasma lipoproteins. Nat Clin Pract Cardiovasc Med 4:600–609. doi:10.1038/ncpcardio1005

    Article  PubMed  CAS  Google Scholar 

  23. Reich DE, Lander ES (2001) On the allelic spectrum of human disease. Trends Genet 17:502–510. doi:10.1016/S0168-9525(01)02410-6

    Article  PubMed  CAS  Google Scholar 

  24. Wang WY, Barratt BJ, Clayton DG et al (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6:109–118. doi:10.1038/nrg1522

    Article  PubMed  CAS  Google Scholar 

  25. Yang Q, Khoury MJ, Friedman J et al (2005) How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 34:1129–1137. doi:10.1093/ije/dyi130

    Article  PubMed  Google Scholar 

  26. Busch CP, Hegele RA (2000) Variation of candidate genes in triglyceride metabolism. J Cardiovasc Risk 7:309–315

    PubMed  CAS  Google Scholar 

  27. Pennacchio LA, Olivier M, Hubacek JA et al (2002) Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11:3031–3038. doi:10.1093/hmg/11.24.3031

    Article  PubMed  CAS  Google Scholar 

  28. Kathiresan S, Melander O, Guiducci C et al (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40:189–197. doi:10.1038/ng.75

    Article  PubMed  CAS  Google Scholar 

  29. Kooner JS, Chambers JC, Aguilar-Salinas CA et al (2008) Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 40:149–151. doi:10.1038/ng.2007.61

    Article  PubMed  CAS  Google Scholar 

  30. Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336. doi:10.1126/science.1142358

    Article  PubMed  CAS  Google Scholar 

  31. Willer CJ, Sanna S, Jackson AU et al (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40:161–169. doi:10.1038/ng.76

    Article  PubMed  CAS  Google Scholar 

  32. Hegele RA, Cao H, Harris SB et al (1999) The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 84:1077–1082. doi:10.1210/jc.84.3.1077

    Article  PubMed  CAS  Google Scholar 

  33. Triggs-Raine BL, Kirkpatrick RD, Kelly SL et al (2002) HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proc Natl Acad Sci USA 99:4614–4619. doi:10.1073/pnas.062059799

    Article  PubMed  CAS  Google Scholar 

  34. McKinney J, Cao H, Behme MT et al (2003) Maturity-onset diabetes of the young (MODY) mutation in type 2 diabetes and latent autoimmune diabetes of the adult. Diabetes Care 26:3358–3359. doi:10.2337/diacare.26.12.3358-a

    Article  PubMed  Google Scholar 

  35. Cohen J, Pertsemlidis A, Kotowski IK et al (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161–165. doi:10.1038/ng1509

    Article  PubMed  CAS  Google Scholar 

  36. Cohen JC, Kiss RS, Pertsemlidis A et al (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869–872. doi:10.1126/science.1099870

    Article  PubMed  CAS  Google Scholar 

  37. Romeo S, Pennacchio LA, Fu Y et al (2007) Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 39:513–516. doi:10.1038/ng1984

    Article  PubMed  CAS  Google Scholar 

  38. Wang J, Cao H, Ban MR et al (2007) Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 27:2450–2455. doi:10.1161/ATVBAHA.107.150680

    Article  PubMed  CAS  Google Scholar 

  39. Wang J, Hegele RA (2007) Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis 6:23. doi:10.1186/1476-511X-6-23

    Article  PubMed  Google Scholar 

  40. Gin P, Beigneux AP, Davies B et al (2007) Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim Biophys Acta 1771:1464–1468

    PubMed  CAS  Google Scholar 

  41. Eichenbaum-Voline S, Olivier M, Jones EL et al (2004) Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24:167–174. doi:10.1161/01.ATV.0000099881.83261.D4

    Article  PubMed  CAS  Google Scholar 

  42. Evans D, Seedorf U, Beil FU (2005) Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet 68:369–372. doi:10.1111/j.1399-0004.2005.00510.x

    Article  PubMed  CAS  Google Scholar 

  43. Henneman P, Schaap FG, Havekes LM et al (2007) Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 193:129–134. doi:10.1016/j.atherosclerosis.2006.05.030

    Article  PubMed  CAS  Google Scholar 

  44. Hubacek JA, Horinek A, Skodova Z et al (2005) Hypertriglyceridemia: interaction between APOE and APOAV variants. Clin Chem 51:1311–1313. doi:10.1373/clinchem.2005.048439

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

RAH is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario (CI-5710), and operating grants from the Canadian Institutes for Health Research (FRN-13430 and MOP-79533), the Heart and Stroke Foundation of Ontario (PRG-5967, NA-6059 and T-6018), the Ontario Research Fund and by Genome Canada through the Ontario Genomics Institute.

Author information

Authors and Affiliations

  1. Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, N6A 5K8, Canada

    Robert A. Hegele & Rebecca L. Pollex

  2. Vascular Biology Research Group, Robarts Research Institute, 406-100 Perth Drive, London, ON, N6A 5K8, Canada

    Robert A. Hegele & Rebecca L. Pollex

  3. Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Drive, London, ON, N6A 5K8, Canada

    Robert A. Hegele

Authors
  1. Robert A. Hegele
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Rebecca L. Pollex
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Robert A. Hegele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hegele, R.A., Pollex, R.L. Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem 326, 35–43 (2009). https://doi.org/10.1007/s11010-008-0005-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-008-0005-1

Keywords